Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Nicholas B Hunt"'
Autor:
Amand F. Schmidt, Nicholas B. Hunt, Maria Gordillo-Marañón, Pimphen Charoen, Fotios Drenos, Mika Kivimaki, Deborah A. Lawlor, Claudia Giambartolomei, Olia Papacosta, Nishi Chaturvedi, Joshua C. Bis, Christopher J. O’Donnell, Goya Wannamethee, Andrew Wong, Jackie F. Price, Alun D. Hughes, Tom R. Gaunt, Nora Franceschini, Dennis O. Mook-Kanamori, Magdalena Zwierzyna, Reecha Sofat, Aroon D. Hingorani, Chris Finan
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Despite being studied in clinical trials, CETP inhibitors are not yet an approved treatment for coronary heart disease. Here, by analyzing results from clinical trials and drug target mendelian randomization studies, the authors demonstrate that prev
Externí odkaz:
https://doaj.org/article/60544e33b7ec4a46bdebdd316f81bb1d
Autor:
Nicholas B. Hunt, Romin Pajouheshnia, Allan Salih, Sander van Doorn, Patrick C. Souverein, Marloes T. Bazelier, Olaf H. Klungel, Helga Gardarsdottir
Publikováno v:
British Journal of Clinical Pharmacology.
Aims: Low-dose rivaroxaban has been indicated for the management of atherosclerotic cardiovascular disease (ASCVD) after recent (2019-2020) updates to European guidelines. We aimed to describe prescription trends of low-dose rivaroxaban in ASCVD pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::07e3251c47df4b0ef306c0a6722305a3
https://doi.org/10.1111/bcp.15708
https://doi.org/10.1111/bcp.15708
Autor:
Romin Pajouheshnia, Marloes T Bazelier, Helga Gardarsdottir, Olaf H. Klungel, Nicholas B Hunt
Publikováno v:
Pharmacoepidemiology and Drug Safety
Pharmacoepidemiology and Drug Safety, 30(7), 819. John Wiley and Sons Ltd
Pharmacoepidemiology and Drug Safety, 30(7), 819. John Wiley and Sons Ltd
Purpose Pharmacoepidemiologic multi‐database studies (MDBS) provide opportunities to better evaluate the safety and effectiveness of medicines. However, the issue of missing data is often exacerbated in MDBS, potentially resulting in bias and preci
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc446b3b4f8e8d16f08ced00fc0c68fd
http://europepmc.org/articles/PMC8252545
http://europepmc.org/articles/PMC8252545
Autor:
Dennis O. Mook-Kanamori, Nora Franceschini, Jackie F. Price, Pimphen Charoen, Reecha Sofat, Amand F. Schmidt, Alun D. Hughes, Aroon D. Hingorani, Nicholas B Hunt, María Gordillo-Marañón, Mika Kivimäki, Goya Wannamethee, Juan-Pablo Casas, Andrew Wong, Claudia Giambartolomei, Magdalena Zwierzyna, Debbie A Lawlor, Olia Papacosta, Joshua C. Bis, Tom R. Gaunt, Nishi Chaturvedi, Chris Finan, Fotios Drenos, Christopher J. O'Donnell
Drug development of cholesteryl ester transfer protein (CETP) inhibition to prevent coronary heart disease (CHD) has yet to deliver licensed medicines. To distinguish compound from drug target failure, we compared evidence from clinical trials and Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d2d63fce5b5363dc3ebc8e7b1e2188ff
https://doi.org/10.1101/2020.09.07.20189571
https://doi.org/10.1101/2020.09.07.20189571
